Canaccord raised the firm’s price target on Heartflow (HTFL) to $39 from $35 and keeps a Buy rating on the shares. The firm updated its model following the release of its 10-Q and itsnew target reflects multiple expansion of the Elite Med-Tech comp group.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- HeartFlow, Inc.: Balancing Impressive Growth with Strategic Challenges – A Hold Recommendation
- HeartFlow Releases Investor Presentation at Healthcare Conference
- Elf Beauty downgraded, Zscaler upgraded: Wall Street’s top analyst calls
- Heartflow initiated with an Equal Weight at Morgan Stanley
- Heartflow initiated with a Buy at Canaccord